Last reviewed · How we verify
AntiCov-220
AntiCov-220 is an antibody that targets the SARS-CoV-2 spike protein.
AntiCov-220 is an antibody that targets the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.
At a glance
| Generic name | AntiCov-220 |
|---|---|
| Also known as | 1a, 1b |
| Sponsor | Nguyen Thi Trieu, MD |
| Drug class | Monoclonal antibody |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | FDA-approved |
Mechanism of action
It works by binding to the spike protein, preventing the virus from entering host cells. This neutralization of the virus is thought to be the primary mechanism of action for AntiCov-220.
Approved indications
- Prevention of COVID-19
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AntiCov-220 CI brief — competitive landscape report
- AntiCov-220 updates RSS · CI watch RSS
- Nguyen Thi Trieu, MD portfolio CI